PFCS
IOVA icon

Pale Fire Capital SE’s Iovance Biotherapeutics IOVA Stock Holding History

Pale Fire Capital SE’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-42,897
Closed -$143K – 67
2025
Q1 		$143K Buy
42,897
+4,022
+10% +$20.7K 0.02% 46
2024
Q4 		$288K Buy
38,875
+1,500
+4% +$13.9K 0.07% 27
2024
Q3 		$351K Buy
37,375
+22,675
+154% +$215K 0.06% 31
2024
Q2 		$118K Buy
14,700
+3,700
+34% +$39.6K 0.01% 35
2024
Q1 		$163K Sell
11,000
-6,024
-35% -$70.1K 0.02% 39
2023
Q4 		$138K Buy
17,024
+1,924
+13% +$10.1K 0.02% 58
2023
Q3 		$68.7K Buy
+15,100
New +$98.6K 0.01% 63

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Pale Fire Capital SE's IOVA Position: Q2 2025 in Review

Pale Fire Capital SE sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 42,897 shares — an estimated $143K sold.

Pale Fire Capital SE first reported a position in IOVA in Q3 2023 and held it in 7 quarters. The position peaked at $351K in Q3 2024. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Pale Fire Capital SE reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Pale Fire Capital SE sold 42,897 Iovance Biotherapeutics shares in Q2 2025, an estimated $143K.
  • Pale Fire Capital SE first reported a position in Iovance Biotherapeutics in Q3 2023 and held it in 7 quarters.
  • Pale Fire Capital SE's Iovance Biotherapeutics position peaked at $351K in Q3 2024.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Pale Fire Capital SE's 13F filing for Q2 2025, filed 13 Aug 2025.